

1 Comparative analysis of human immune responses following SARS-CoV-2 vaccination  
2 with BNT162b2, mRNA-1273, or Ad26.COV2.S

3

4 Dominique J. Barbeau<sup>1,2</sup>, Judith M. Martin<sup>1,4,\*</sup>, Emily Carney<sup>1</sup>, Emily Dougherty<sup>1</sup>, Joshua  
5 D. Doyle<sup>1,2,4</sup>, Terence S. Dermody<sup>1,3,4</sup>, Alejandro Hoberman<sup>1,3,4</sup>, John V. Williams<sup>1,4</sup>,  
6 Marian G. Michaels<sup>1,4</sup>, John F. Alcorn<sup>1</sup>, W. Paul Duprex<sup>2,3</sup>, Anita K. McElroy<sup>1,2,4\*</sup>

7

8 <sup>1</sup>Department of Pediatrics, <sup>2</sup>Center for Vaccine Research, <sup>3</sup>Department of Microbiology  
9 and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA,  
10 USA

11 <sup>4</sup>Institute of Infection, Inflammation, and Immunity, UPMC Children's Hospital of  
12 Pittsburgh, Pittsburgh, PA, USA

13

14 Keywords: SARS-CoV-2, immunogenicity, vaccine

15 Running title: Immune comparison of SARS-CoV-2 vaccines

16

17 \*Corresponding author: AKM: 3501 Fifth Ave, Pittsburgh, PA 15261 [mcelroya@pitt.edu](mailto:mcelroya@pitt.edu),

18 412-648-4026

19 Alternate corresponding author: JMM: 4401 Penn Ave. Pittsburgh, PA 15224

20 [martinju@pitt.edu](mailto:martinju@pitt.edu), 412-692-7232

21

22 40 word summary of key points: We compared antigen specific humoral and T cell

23 responses following vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S. Both

24 mRNA based vaccines elicited higher magnitude humoral responses than  
25 Ad26.COVS and mRNA1273 elicited the highest magnitude of T cell response.

26

27 Word count: 2610 (3000 max)

28

29 **Abstract: (words 207, 250 max)**

30 Background: Three SARS-CoV-2 vaccines, two based on mRNA, BNT162b2 and  
31 mRNA-1273, and one based on an adenovirus platform, Ad26.COVS, received  
32 emergency use authorization by the U.S. Food and Drug Administration in 2020/2021.

33 These vaccines displayed clinical efficacy in initial studies against confirmed COVID-19  
34 of 95.0%, 94.1%, and 66.9%, respectively.

35 Methods: Individuals receiving one of these vaccines were invited to participate in a  
36 prospective longitudinal comparative study of immune responses elicited by the three  
37 vaccines. In this observational cohort study, humoral responses were evaluated using a  
38 SARS-CoV-2 receptor-binding domain (RBD) ELISA and a SARS-CoV-2 virus  
39 neutralization assay at mean of 21-31 days and 45-63 days following each initial  
40 vaccination. IFN- $\gamma$  ELISPOT assays were conducted with peripheral blood mononuclear  
41 cells obtained at a median of 45-63 days after each initial vaccination.

42 Results: The two mRNA-based platforms elicited similar RBD ELISA responses and  
43 neutralizing antibody responses. The adenovirus-based vaccine elicited significantly  
44 lower RBD ELISA and SARS-CoV-2 virus neutralization activity. The mRNA-1273  
45 vaccine elicited significantly higher spike glycoprotein-specific T cell responses than  
46 either the BNT162b2 or the Ad26.COVS vaccines.

- 47 Conclusions: Both mRNA based vaccines elicited higher magnitude humoral responses  
48 than Ad26.COV2.S and mRNA1273 elicited the highest magnitude of T cell response.  
49 Neutralizing antibody titers correlated with reported estimates of vaccine efficacy.

50 **Introduction:**

51 Two mRNA-based vaccines (BNT162b2 and mRNA-1273) and one adenovirus-based  
52 vaccine (Ad26.COV2.S) have been used in the US since EUA was granted for each  
53 (December 2020 for the mRNA vaccines and February 2021 for the adenovirus  
54 vaccine). While data have been published for each of these vaccines confirming safety,  
55 immunogenicity, and efficacy [1-7], only limited data are available that compare vaccine-  
56 induced immune responses amongst the three vaccines using identical immunological  
57 assays [8]. In this study, we assessed a cohort of SARS-CoV-2 naive individuals who  
58 received BNT162b2, mRNA-1273, or Ad26.COV2.S vaccines for antigen-specific  
59 humoral and T cell immunity using identical immunologic assays to allow direct  
60 comparisons of the elicited responses. To date, an immune correlate of protection has  
61 not been established, however, neutralizing antibody titers may be a possible correlate  
62 [9]. Mathematical modelling combined with analysis of published immunogenicity data  
63 has been used to demonstrate that the ratio of neutralization titer following vaccination  
64 to that during convalescence following naturally-acquired disease correlates with the  
65 reported clinical efficacy for each vaccine [10]. Our study demonstrates a correlation  
66 between neutralizing antibody titer and reported vaccine efficacy, but we did not  
67 observe this correlation with IFN- $\gamma$  ELISPOT responses, supporting the use of  
68 neutralizing antibody titer as a correlate of protection.

69 **Methods:**

70 *Human subjects research:*

71 A convenience sample of participants 18 years of age and older were prospectively  
72 enrolled if they were planning to receive two doses of mRNA-1273 or BNT162b2, or a

73 single dose of Ad26.COV2.S under FDA EUA between December 2020 and March  
74 2021 either in an occupational (BNT162b2) or a community (mRNA-1273 and  
75 Ad26.COV2.S) setting. After obtaining written informed consent, whole blood was  
76 obtained in cell preparation tubes (BD) on the day of enrollment/first vaccination, and  
77 during follow up visits. Plasma and peripheral blood mononuclear cells (PBMCs) were  
78 isolated and cryopreserved using standard methods. Institutional Review Board  
79 approval was provided by the University of Pittsburgh Human Research Protection  
80 Office.

81 *Enzyme-linked immunosorbent assay (ELISA) and focus reduction neutralization*  
82 *assays (FRNT)*

83 ELISA and FRNT assays were conducted as previously described [11]. Samples with  
84 FRNT<sub>50</sub> titers below the limit of detection (LOD=10) were assigned a value of 5 for  
85 graphical depiction and statistical analysis on the figures.

86 *ELISPOT assays*

87 PMBCs were incubated for 24 hours with 2 µg/mL of a SARS-CoV-2 complete spike  
88 glycoprotein mega pool consisting of 15-mer peptides overlapping by 11 residues based  
89 upon the original Wuhan-Hu-1 strain (GenBank MN908947.3) (Miltenyi) with 1 x Cell  
90 Activation Cocktail (without Brefeldin A, BioLegend) or media alone. Human IFN-γ  
91 ELISPOT assays were conducted according to the manufacturer's instructions  
92 (Mabtech).

93 *Data analysis*

94 Graphpad Prism was used for statistical analysis and to prepare figures. Four samples  
95 were missing from visit 2 for the mRNA-1273 participants. Samples were available for

96 all other participants at all time points. To analyze ELISA data a mixed-effects model  
97 with the Geisser-Greenhouse correction and Tukey's multiple comparison test was  
98 used. To analyze FRNT data, a mixed-effects model and Sidak's multiple comparison  
99 test was used. A Kruskal-Wallis test with Dunn's multiple comparisons test was used to  
100 compare ELISPOT data between vaccine groups. Sex, age, and racial/ethnic  
101 distributions of participants were compared with those of the catchment area using one-  
102 way chi-squared goodness-of-fit tests.

103

#### 104 **Results:**

105 Participant age, sex, and race were provided at the time of enrollment (Table 1).

106 Information about co-morbidities was collected from the medical record or directly from  
107 study participants.

108 An RBD ELISA was conducted using plasma samples from all participants at all three  
109 time points (enrollment/date of first vaccination and at subsequent visits, Table 2).

110 Participants with higher-than-average baseline RBD titers were tested by SARS-CoV-2  
111 nucleoprotein (N) ELISA, and 5 individuals were found to have N-specific ELISA titers  
112 greater than or equal to 900 [11]. As this finding is consistent with prior SARS-CoV-2  
113 infection, data from these participants were excluded from further analysis. One mRNA-  
114 1273 vaccine recipient relocated after enrollment precluding collection of additional  
115 data. After these exclusions, 25 BNT162b2 recipients, 24 mRNA-1273 recipients, and  
116 24 Ad26.COVS recipients were included in the study. On the date of first vaccination  
117 (pre-bleed), 6 individuals had detectable RBD ELISA titers relative to a pre-pandemic  
118 normal human control group. There were no statistically significant differences in

119 baseline titers between the vaccine groups (Figure 1). At visit 2 (median 21-31 days  
120 post initial vaccination), most study participants had notable antibody titers with the  
121 exception of two BNT162b2 recipients, one of whom was immunocompromised  
122 secondary to ongoing therapy for breast cancer with capecitabine. At visit 2, RBD  
123 ELISA titers were significantly higher in mRNA-1273 recipients compared with  
124 Ad26.COVS recipients ( $p=0.0008$ ) At visit 3 (median 45-63 days post initial  
125 vaccination), following booster doses for both of the mRNA-based vaccines, the  
126 BNT162b2 titers were equivalent to the mRNA-1273 titers, and both were significantly  
127 higher than those achieved by the Ad26.COVS (single-dose regimen) ( $p=0.0059$  for  
128 BNT162b2 vs. Ad26.COVS and  $p=0.0315$  for mRNA-1273 vs. Ad26.COVS). RBD  
129 ELISA titers observed in these cohorts correlated with those previously reported in  
130 immunogenicity studies of the various vaccines with Ad26.COVS having 2-3 log GMT  
131 [6], and mRNA-1273 and BNT162b2 having 4-5 log GMT after completion of the two  
132 dose series [3, 12].

133 Plasma samples from visit 2 and visit 3 were tested in a neutralization assay using  
134 SARS-CoV-2. FRNT<sub>50</sub> titers were at or below the limit of detection (LOD=10) for a small  
135 subset of participants after a single immunization and did not differ significantly between  
136 vaccines (Figure 2A). Following a second dose of either of the mRNA vaccines, FRNT<sub>50</sub>  
137 titers were significantly higher than those achieved with single dose Ad26.COVS  
138 vaccination ( $p<0.0001$  for both BNT162b2 and mRNA-1273 vs. Ad26.COVS). A trend  
139 towards higher mean FRNT<sub>50</sub> titer was observed following the vaccination series with  
140 mRNA-1273 than with BNT162b2, but this was not significant. Given the relatively low  
141 neutralization titers observed in some subjects, several observations did not meet the

142 50% focus-reduction threshold. Therefore, the data were analyzed as a function of  
143 percent neutralization of input virus at a constant 1:20 dilution of plasma (Figure 2B).  
144 This strategy allowed a more nuanced assessment of the capacity of individual plasma  
145 specimens to neutralize virus. Participants who received a single dose of mRNA-1273  
146 achieved higher percent neutralization at 1:20 dilution than those receiving  
147 Ad26.COVS2.S ( $p < .0001$ ). Following the booster dose, BNT162b2 and mRNA-1273  
148 vaccination elicited similar neutralizing capacity, and percent neutralization at 1:20  
149 dilution elicited by both mRNA vaccines was higher in magnitude than that elicited by  
150 the single dose Ad26.COVS2.S at visit 3 ( $p < 0.0001$  for both BNT162b2 and mRNA-1273  
151 versus Ad26.COVS2.S). Interpretation of these data in the context of previous  
152 independently published reports of each vaccine should take into consideration the  
153 differences in methods used in these studies. In some studies, pseudovirion assays are  
154 used, in others live virus is used but the readouts vary based upon the assay- luciferase  
155 reporters in some, foci in others. Additionally, if the inoculum (virus combined with  
156 serum) is left in place following adsorption, this could alter the assay to assess not only  
157 antibodies that block binding but also those that block cell to cell spread or post-binding  
158 steps in fusion as has been shown for antibodies that target the spike N-terminal  
159 domain [13, 14]. Slightly lower FRNT<sub>50</sub> titers noted in our study could be because we  
160 remove the inoculum after a 1-hour incubation period, hence our FRNT assay is specific  
161 for antibodies that block binding to the cellular ACE2 receptor. For this reason it is  
162 important to have a comparator control group that can be used in all studies to permit  
163 normalizing between assays as has been proposed by WHO [15].



164 SARS-CoV-2 spike glycoprotein-specific T cell responses were assessed using an IFN-  
165  $\gamma$  ELISPOT assay with PMBCs from study participants at visit 3 (Figure 3). mRNA-1273  
166 recipients had a significantly higher magnitude of IFN- $\gamma$  producing T cells following *ex*  
167 *vivo* stimulation of PBMCs with a total spike peptide mega pool when compared with  
168 BNT162b2 and Ad26.COVS recipients ( $p < 0.0001$  for BNT162b2 vs. mRNA-1273 and  
169  $p = 0.0001$  for Ad26.COVS vs. mRNA-1273). No significant differences in T cell  
170 responses were apparent between the BNT162b2 and Ad26.COVS recipients.

### 171 **Discussion:**

172 *Comparative humoral immune responses correlated with published efficacy data.* The  
173 mRNA-1273 vaccine trended towards the greatest magnitude of spike-specific humoral  
174 immunity. This was also recently reported in another study of humoral immunity  
175 following vaccination [16]. The mRNA-1273 vaccine contains 100  $\mu\text{g}$  of mRNA encoding  
176 the full-length, stabilized spike glycoprotein[2]. In our small cohort, BNT162b2 achieved  
177 a similar magnitude of antibody response after the second dose. The BNT162b2  
178 vaccine contains 30  $\mu\text{g}$  of mRNA encoding the full-length, stabilized spike glycoprotein  
179 [4]. The Ad26.COVS vaccine is administered at a dose of  $5 \times 10^{10}$  virus particles [5].  
180 The adenovirus vector is replication-incompetent, thus, similar to the mRNA vaccines,  
181 only cells that take up the vaccine following inoculation will produce the SARS-CoV-2  
182 spike glycoprotein. There is no amplification of these three vaccines *in vivo*. Data on  
183 humoral immune responses suggest a correlation between the dose of antigen and the  
184 kinetics and magnitude of the response, at least for the mRNA vaccines. Accordingly, a  
185 dose-response was reported in early Phase I/II clinical trials of all three of the vaccine  
186 platforms [3, 6, 7, 12]. However, as with all vaccines, the goal is to achieve a balance

187 between reactogenicity and immunogenicity. Significant reactogenicity was reported in  
188 mRNA-1273 clinical trials and greater than 50% of study subjects reported a systemic  
189 adverse reaction of any grade after the first dose and over 75% after the second dose  
190 [2]. The BNT162b2 vaccine also had significant reactogenicity [4] but with lower  
191 frequency than mRNA-1273. Following single dose Ad26.COVS.S vaccination, over  
192 60% of participants reported a systemic adverse reaction of any grade [5]. Significant  
193 reactogenicity in the setting of lower immunogenicity with the adenovirus vaccine might  
194 be attributable to pre-existing immunity to adenovirus or activation of innate immune  
195 pathways that differ from the mRNA vaccines.

196 A ratio of vaccine/convalescent neutralization titer may represent an immunologic  
197 surrogate of protection [10]. In our previous work evaluating neutralization titers of  
198 individuals with serologically-identified prior infection (n=30), we found a FRNT<sub>50</sub> GMT  
199 of 130 [11]. Similarly, we measured a FRNT<sub>50</sub> GMT of 129.6 and in a cohort of  
200 virologically confirmed outpatients (n=56) (unpublished data). The FRNT<sub>50</sub> GMT for  
201 each vaccine at visit 3 for samples with a positive value was 223.2 for BNT162b2, 348.9  
202 for mRNA-1273, and 20.7 for Ad26.COVS.S. These values would result in a ratio of  
203 vaccine/convalescent titer of approximately 1.7 for BNT162b2, 2.7 for mRNA-1273, and  
204 0.2 for Ad26.COVS.S, which would equate to a predicted protective efficacy of >90% for  
205 the two mRNA vaccines and approximately 50% for the adenovirus-based vaccine as  
206 extrapolated from Khoury et al [10]. These predicted efficacy estimates are similar to the  
207 observed estimates of 94.1-95.0% vaccine effectiveness for the two mRNA vaccines [2,  
208 4], providing support for the use of vaccine/convalescent titer as a correlate of  
209 protection. However, our calculated value of predicted efficacy for the Ad26.COVS.S

210 vaccine group (approximately 50%) was slightly lower than that observed in the Phase  
211 III clinical trial for Ad26.COVS.S (66.9%) [5], which may be attributable to the fact that  
212 our Ad26.COVS.S cohort is mostly older men or it could be attributable to the difficulty of  
213 comparing data using different immunological assays and the lack of a clear definition of  
214 “convalescent” in the calculation of GMT from convalescent patients. Further studies are  
215 necessary to confirm a precise serum neutralizing titer that correlates with protection  
216 and to identify and standardize assays for this determination.

217 *Antigen-specific T cells do not necessarily correlate with vaccine efficacy.* When our T  
218 cell data are compared with published data from initial immunogenicity studies for  
219 Ad26.COVS.S, the data are concordant with Ad26.COVS.S Phase 1-2a data showing  
220 IFN- $\gamma$  ELISPOT mean of approximately 180 spot forming units (SFU) per  $1 \times 10^6$  PMBC  
221 [6] and our data showing a mean of 14 spot forming units per  $1 \times 10^5$  PMBC. The initial  
222 immunogenicity trials for mRNA-1273 and BNT162b2 did not report on T cell studies.  
223 Since their publication, several studies have assessed T cells in older adults,  
224 immunocompromised hosts or in mixed cohorts of mRNA vaccine recipients and T cell  
225 responses; one study largely composed of BNT126b recipients had SFU ranging from  
226 the LOD to 1000 per  $1 \times 10^6$  PMBC [17] which is consistent with our data showing SFU  
227 ranging from 0 to 100 per  $1 \times 10^5$  PMBC. This assay is another area in which  
228 standardization is needed for cross study comparison.

229 The finding of significantly higher levels of spike-specific T cells following vaccination  
230 with mRNA-1273 than with either BNT162b2 or Ad26.COVS.S could be attributable to  
231 higher levels of antigen or to the dosing regimen. A notable feature of all three vaccines  
232 is the intracellular expression of viral antigen, which allows intracellular processing and

233 presentation of spike glycoprotein-derived peptides in the context of MHC I and  
234 stimulation of virus-specific T cell responses. Intracellular antigen expression is an  
235 advantage of viral-vectored vaccine platforms such as adenovirus-based vaccines.  
236 However, as our data demonstrate, mRNA vaccines elicit equivalent (BNT162b2) or  
237 higher-magnitude (mRNA-1273) antigen-specific T cell responses compared to  
238 Ad26.COVS. These data have an additional important implication. Clinical trials  
239 indicated that BNT162b2 has an efficacy of 95% after the two-dose series, while  
240 Ad26.COVS efficacy was 66.9%. Since these two vaccines elicit similar T cell  
241 responses in IFN- $\gamma$  ELISPOT assays, these data suggest that the T cell component of  
242 the immune response is probably not responsible for the enhanced protection afforded  
243 by BNT162b2 versus Ad26.COVS. However, the IFN- $\gamma$  ELISPOT assay did not  
244 discriminate between CD4+ and CD8+ T cells, and thus, we cannot exclude the  
245 possibility that a specific T cell subset or function plays a role in protection, or that T cell  
246 mediated protection plays a role in the context of reduced humoral immunity.

247 *Could antigen-specific T cells provide a protective advantage against variants of*  
248 *concern?* One of the most pressing problems in the pandemic is the emergence of viral  
249 variants of concern (VOC). Serum from vaccine recipients appears to neutralize the  
250 variants reported thus far, despite a reduction in viral neutralizing capacity in some  
251 cases [18-21]. Additionally, vaccinated individuals appear to be protected from severe  
252 disease and hospitalization following infection with VOC [22]. Studies of influenza  
253 vaccination suggest that heterologous protection is provided by virus-specific T cell  
254 immunity [23]. Most SARS-CoV-2 T cell epitopes are largely conserved between the  
255 variants [24], and even unexposed individuals have some virus-specific T cells due to

256 cross-reactivity with epitopes conserved among common human coronaviruses [25].

257 Given the existence of virus-specific, cross-reacting T cells, we hypothesize that  
258 increased protection from disease caused by the variants could be provided by vaccines  
259 that also stimulate strong T cell responses in addition to strong humoral responses. If  
260 this were the case, mRNA-1273 could potentially provide better protection from variants  
261 than either BNT162b2 or Ad26.COV2.S. Further research will be required to test this  
262 hypothesis.

263 Limitations of our study include that it was an observational cohort study without  
264 randomization, and participants receiving the various vaccines were not matched for  
265 demographics. As a result, there were sex and age differences and different racial  
266 distributions between the groups. The cohorts were of insufficient size to permit sub-  
267 group comparisons. The different dosing regimens between the vaccines resulted in  
268 slightly different intervals post vaccination for sampling and could have influenced the  
269 observed immunogenicity of the various vaccines. Despite these limitations, our findings  
270 are consistent with published efficacy data for these three vaccines and provide a direct  
271 side-by-side assessment of the elicited immune responses.

272 Vaccination can provide protection from infection, disease, and/or death. All of these are  
273 achievable aims depending on the level and type of immunity induced by the vaccine.  
274 Moreover, protection from infection and potentially from disease also is likely to  
275 decrease transmission. As all these vaccine effects contribute to the control of the  
276 COVID-19 pandemic, a given vaccine can be effective in advancing public health goals  
277 without necessarily inducing the highest magnitude of immune response.

278

279 **Funding:** This work was supported by R. K. Mellon Foundation to [JM, AH, TD, WPD],  
280 University of Pittsburgh Center for Vaccine Research and Henry L. Hillman Foundation  
281 to [WPD], UPMC Children’s Hospital to [JVW, MM, AKM], and Burroughs Wellcome  
282 Fund [1013362.02 to AKM].

283

284 **Acknowledgements:** The authors acknowledge Saran Kupul and Lucas Schratz for  
285 assistance with sample processing, Melissa Andrasko, Spenser Kinsey, Lisa Vavro,  
286 Lalicia Roman, Jennifer Opal and Shannon Mance for assisting with subject enrollment  
287 and specimen collection, Pediatric Infectious Disease clinical research coordinators  
288 Samar Musa, Sophia Kainaroi and Isaac Cason for assistance with scheduling, and the  
289 UPMC Children’s Hospital Laboratory for assistance with subject phlebotomy

290

291

292 **Disclosures:** JMM and AH receive funding from NIH/NIAID (UM1AI148452) and are  
293 investigators for the adult mRNA1273 and Ad26.COVID.S phase 3 vaccine studies. JVW  
294 serves on the Scientific Advisory Board of Quidel and an Independent Data Monitoring  
295 Committee for GlaxoSmithKline, neither related to the present work.

296

297 **Author Contributions:**

298 DJB: data acquisition and analysis, manuscript review and editing

299 EC: data acquisition, manuscript review and editing

300 ED: data acquisition, manuscript review and editing

301 JD: data acquisition and analysis, manuscript review and editing

- 302 TD: study concept and design, funding acquisition, manuscript review and editing
- 303 AH: study concept and design, funding acquisition, data acquisition, manuscript review
- 304 and editing
- 305 JWV: study concept and design, funding acquisition, manuscript review and editing
- 306 MGM: study concept and design, manuscript review and editing
- 307 JFA: study concept and design, data acquisition, manuscript review and editing
- 308 WPD: study concept and design, funding acquisition, manuscript review and editing
- 309 JMM: study concept and design, IRB approval, data acquisition, study oversight,
- 310 funding acquisition, manuscript review and editing
- 311 AKM: study concept and design, IRB approval, study oversight, funding acquisition,
- 312 data acquisition, analysis and interpretation, manuscript writing, review and editing,
- 313
- 314
- 315
- 316

## 317 References

- 318 1. Alter G, Yu J, Liu J, et al. Immunogenicity of Ad26.COVS vaccine against  
319 SARS-CoV-2 variants in humans. *Nature* **2021**.
- 320 2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273  
321 SARS-CoV-2 Vaccine. *N Engl J Med* **2021**; 384(5): 403-16.
- 322 3. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against  
323 SARS-CoV-2 - Preliminary Report. *N Engl J Med* **2020**; 383(20): 1920-31.
- 324 4. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2  
325 mRNA Covid-19 Vaccine. *N Engl J Med* **2020**; 383(27): 2603-15.
- 326 5. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose  
327 Ad26.COVS Vaccine against Covid-19. *N Engl J Med* **2021**; 384(23): 2187-  
328 201.
- 329 6. Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1-2a Trial of  
330 Ad26.COVS Covid-19 Vaccine. *N Engl J Med* **2021**; 384(19): 1824-35.
- 331 7. Stephenson KE, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COVS  
332 Vaccine for COVID-19. *JAMA* **2021**; 325(15): 1535-44.
- 333 8. Zhou H, Fang Y, Xu T, Ni WJ, Shen AZ, Meng XM. Potential therapeutic targets  
334 and promising drugs for combating SARS-CoV-2. *Br J Pharmacol* **2020**; 177(14):  
335 3147-61.
- 336 9. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a  
337 protective correlate for COVID-19 vaccines. *Vaccine* **2021**.
- 338 10. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly  
339 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat*  
340 *Med* **2021**.
- 341 11. Xu L, Doyle J, Barbeau DJ, et al. A Cross-Sectional Study of SARS-CoV-2  
342 Seroprevalence between Fall 2020 and February 2021 in Allegheny County,  
343 Western Pennsylvania, USA. *Pathogens* **2021**; 10(6).
- 344 12. Walsh EE, Frenck RW, Jr., Falsey AR, et al. Safety and Immunogenicity of Two  
345 RNA-Based Covid-19 Vaccine Candidates. *N Engl J Med* **2020**; 383(25): 2439-  
346 50.
- 347 13. McCallum M, De Marco A, Lempp FA, et al. N-terminal domain antigenic  
348 mapping reveals a site of vulnerability for SARS-CoV-2. *Cell* **2021**; 184(9): 2332-  
349 47 e16.
- 350 14. Suryadevara N, Shrihari S, Gilchuk P, et al. Neutralizing and protective human  
351 monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2  
352 spike protein. *Cell* **2021**; 184(9): 2316-31 e15.
- 353 15. Kristiansen PA, Page M, Bernasconi V, et al. WHO International Standard for  
354 anti-SARS-CoV-2 immunoglobulin. *Lancet* **2021**; 397(10282): 1347-8.
- 355 16. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-  
356 CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-  
357 1273. *JAMA* **2021**.
- 358 17. Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines  
359 induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and  
360 HCoV-NL63. *J Clin Invest* **2021**; 131(10).



- 361 18. Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-  
362 CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *Lancet* **2021**;  
363 397(10292): 2331-3.
- 364 19. Muik A, Wallisch AK, Sanger B, et al. Neutralization of SARS-CoV-2 lineage  
365 B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. *Science* **2021**;  
366 371(6534): 1152-3.
- 367 20. Edara VV, Floyd K, Lai L, et al. Infection and mRNA-1273 vaccine antibodies  
368 neutralize SARS-CoV-2 UK variant. *medRxiv* **2021**.
- 369 21. Barouch DH, Stephenson KE, Sadoff J, et al. Durable Humoral and Cellular  
370 Immune Responses Following Ad26.COVS Vaccination for COVID-19.  
371 *medRxiv* **2021**: 2021.07.05.21259918.
- 372 22. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health S, the EIIIC.  
373 SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission,  
374 and vaccine effectiveness. *Lancet* **2021**; 397(10293): 2461-2.
- 375 23. Balz K, Trassl L, Hartel V, Nelson PP, Skevaki C. Virus-Induced T Cell-Mediated  
376 Heterologous Immunity and Vaccine Development. *Front Immunol* **2020**; 11: 513.
- 377 24. Tarke A, Sidney J, Methot N, et al. Negligible impact of SARS-CoV-2 variants on  
378 CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and  
379 vaccinees. *bioRxiv* **2021**.
- 380 25. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-  
381 CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed  
382 Individuals. *Cell* **2020**; 181(7): 1489-501 e15.

384

385 **Table 1: Demographics of the study population**

Characteristic	No. (%)						
	BNT162b 2 (N = 25)	p value <sup>c</sup>	mRNA- 1273 (N = 24)	p value <sup>c</sup>	Ad26.COVID. S (N = 24)	p value <sup>c</sup>	Catchme nt area <sup>a</sup> (N = 1216045)
<b>Sex</b>		0.0003		0.142		0.027	
<b>Female</b>	22 (88)		16 (67)		7 (29)		588306 (51.7)
<b>Male</b>	3 (12)		8 (33)		17 (71)		627739 (48.3)
<b>Age group (yrs)<sup>b</sup></b>		0.267		0.449		0.689	
<b>20-29</b>	8 (32)		5 (21)		4 (17)		166861 (17.4)
<b>30-39</b>	7 (28)		6 (25)		4 (17)		175986 (18.4)
<b>40-49</b>	3 (12)		2 (8)		4 (17)		135028 (14.1)
<b>50-59</b>	3 (12)		2 (8)		6 (25)		154808 (16.1)
<b>60-69</b>	3 (12)		7 (29)		5 (21)		166603 (17.4)
<b>70-79</b>	1 (4)		2 (8)		1 (4)		94691 (9.9)
<b>80+</b>	0 (0)		0 (0)		0 (0)		64625 (6.7)
<b>Race/Ethnicity</b>		0.444		0.003		0.000	

3

<b>White, non-</b>	23 (92)	19 (79)	17 (71)	948157
<b>Hispanic</b>				(78.0)
<b>Black, non-</b>	1 (4)	0 (0)	1 (4)	155798
<b>Hispanic</b>				(12.8)
<b>Hispanic</b>	0 (0)	3 (13)	1 (4)	27552
				(2.3)
<b>Asian/Pacific</b>	0 (0)	2 (8)	5 (21)	46643
<b>Islander, non-</b>				(3.8)
<b>Hispanic</b>				
<b>Multiple race</b>	1 (4)	0 (0)	0 (0)	37895
<b>/Other/Unknown</b>				(3.1)

386 **Source:** United States Census Bureau, 2019 American Community Survey 1-year

387 estimates

388 <sup>a</sup> Allegheny County, Pennsylvania

389 <sup>b</sup> Age groups for catchment area based on estimates for population aged >19y (N =

390 958602)

391 <sup>c</sup> One-way chi-squared goodness-of-fit tests comparing sample with catchment area

392 demographics

393

394 **Table 2: Intervals between vaccination and follow up visits for each vaccine**  
 395 **group**

396

<b>Median # Days (Interquartile Range)</b>	<b>mRNA-1273</b>	<b>BNT162b2</b>	<b>Ad26-COV2.S</b>
<b>Interval between vaccine 1 and visit 2</b>	28 (27-29)	21 (17-22)	31 (28-35)
<b>Interval between vaccine 1 and visit 3</b>	63 (60-68)	45 (43-46)	60 (56-66)
<b>Interval between vaccine 2 and visit 3</b>	36 (32-41)	24 (22-25)	N/A

397

398

399

400 **Figure 1: RBD ELISA titers amongst vaccine recipients.** Plasma from each timepoint  
401 was tested by an RBD ELISA. Each data point is shown, the geometric mean and  
402 geometric standard deviation are plotted. The dotted line is the limit of detection of the  
403 assay. Statistically significant differences are noted by the respective p value.


404

405 **Figure 2: SARS-CoV-2 virus neutralization amongst vaccine recipients.** Plasma from  
406 each timepoint was tested by a SARS-CoV-2 neutralization assay. Data are shown as  
407 FRNT<sub>50</sub> (A) and as the percent of neutralization of input virus achieved at a 1:20 dilution of  
408 plasma (B). Each data point is shown, the geometric mean and geometric standard  
409 deviation (A) or mean and standard deviation (B) are plotted. Statistically significant  
410 differences are noted by the respective p value. The limit of detection for the FRNT<sub>50</sub> assay  
411 is a titer of 10, indicated by a dotted line. The geometric mean titer (GMT) of a series of  
412 convalescent patients is indicated by a dashed line.

413


414 **Figure 3: SARS-CoV-2 spike protein-specific T cell responses amongst vaccine**  
415 **recipients.** PBMCs from the visit 3 timepoint were tested by an IFN gamma ELISPOT  
416 assay. Data are shown as spot forming units (SFU) per 100,000 PBMCs. Each data point is  
417 shown, the mean and standard deviation are plotted. Statistically significant differences are  
418 noted by the respective p value.

**Figure 1**




**Figure 1: RBD ELISA titers amongst vaccine recipients.** Plasma from each timepoint was tested by an RBD ELISA. Each data point is shown, the geometric mean and geometric standard deviation are plotted. The dotted line is the limit of detection of the assay. Statistically significant differences are noted by the respective p value.

Figure 2



**Figure 2: SARS-CoV-2 virus neutralization amongst vaccine recipients.** Plasma from each timepoint was tested by a SARS-CoV-2 neutralization assay. Data are shown as  $\text{FRNT}_{50}$  (A) and as the percent of neutralization of input virus achieved at a 1:20 dilution of plasma (B). Each data point is shown, the geometric mean and geometric standard deviation (A) or mean and standard deviation (B) are plotted. Statistically significant differences are noted by the respective p value. The limit of detection for the  $\text{FRNT}_{50}$  assay is a titer of 10, indicated by a dotted line. The geometric mean titer (GMT) of a series of convalescent patients is indicated by a dashed line.

**Figure 3**



**Figure 3: SARS-CoV-2 spike protein-specific T cell responses amongst vaccine recipients.** PBMCs from the visit 3 timepoint were tested by an IFN gamma ELISPOT assay. Data are shown as spot forming units (SFU) per 100,000 PBMCs. Each data point is shown, the mean and standard deviation are plotted. Statistically significant differences are noted by the respective p value.